Streamex is no longer the cardiac-signal company that listed as BioSig. After buying a Vancouver tokenization shop last spring and renaming the parent last September, the equity is a bet that a yield-bearing gold token can become a real asset franchise rather than a self-funded demonstration. The second quarter is the first period with recognized gold-lease income, and the balance sheet is clean of funded debt after the winter recapitalization. What did not arrive is scale. Assets in the flagship token barely moved, and the issuer still owns most of the float it seeded.
That gap is the whole debate. Management spent the quarter wiring custody, an alternative trading system, a market maker, a qualified custodian, and an independent reserve attestation around a product that already pays gold into holder wallets. Those pipes are real, and they remove the operational excuses that usually kill a first token. They do not, by themselves, create third-party demand. External holders still own only a sliver of GLDY, the company still carries the physical gold on its own books at cost, and a digital-asset loan plus a locked fund stake keep part of the advertised liquidity from being spendable cash. Cost cuts look large because stock-based compensation collapsed from the first-quarter spike, not because the platform suddenly covers its keep.
The next several prints settle whether the distribution stack converts into allocations, or whether the market is looking at a recapitalized shell that proved a mechanism and then stalled. Watch ounces outstanding and the external share of those ounces, the first named institutional ticket, and whether the permissionless gold token actually compounds the reserve instead of just restating it. The share price already sits under a dollar, so listing mechanics sit next to product mechanics as a second clock.